Market Overview

UPDATE: Stifel Nicolaus Cuts PT to $26 on Ariad Pharmaceuticals on Tempered Iclusig Outlook

Related ARIA
GNC, Southern Copper And Others Insiders Have Been Buying
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel

Stifel Nicolaus maintained Ariad Pharmaceuticals (NASDAQ: ARIA) with a Buy rating and lowered the price target from $27.00 to $26.00.

Stifel Nicolaus noted, "We surveyed 34 hematology/oncology specialists in February. Results continue to suggest best-in-class potential for Iclusig in third-line and later-line therapy but greater uncertainty than before regarding Iclusig's front-line potential on the heels of black box warnings for thrombosis and hepatotoxicity. We decrease our target price to $26 from $27 as we decrease our Iclusig sales and out-year EPS estimates."

Ariad Pharmaceuticals closed at $20.08 on Wednesday.

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (ARIA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters